Clinical Trial Update: Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 clinical trial evaluating the combination of Apatinib Mesylate and the PD-1 inhibitor camrelizumab (SHR-1210) in hepatocellular c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (SHR-1210) (camrelizumab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN